A study found that a simplified artificial circuit, modeled after the brain's neuronal system, can predict network activity and provide insights into how the brain manages short-term memory, with potential implications for novel treatments of eye movement disorders.
The incidence was comparable to that of daily wear soft contact lenses.
ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.
A study by a team of Chinese researchers highlights the potential of optical coherence tomography angiography (OCTA) in detecting retinal microvascular damage in renal hypertension patients. OCTA identifies reduced vascular density in key retinal regions, offering a noninvasive tool for early diagnosis and systemic disease management.
Today’s technology proves faster, better, cheaper.
Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are exposed to low humidity, strong ultraviolet rays, cold and dry weather, and low pressure and hypoxia
The NHS is expanding the use of optical coherence tomography to enhance diabetic eye care, aiming to improve early detection of diabetic retinopathy and reduce the backlog of hospital appointments.
The program aims to expand access and affordability for Harrow's ophthalmic pharmaceutical products through targeted price reductions and a strategic partnership with GoodRx.
Research is needed to establish the best diagnostic and management strategies for increasingly common condition
This Week in Ophthalmology is a weekly video series highlighting the latest news and articles featured on the Ophthalmology Times website.
The CHMP has recommended FYB203 for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.
Cerebral/cortical visual impairment (CVI) is a leading cause of childhood blindness, caused by brain damage to visual pathways. Researchers are refining its definition and diagnostic methods to improve early detection and treatment, enhancing outcomes for affected children.
Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.
After closing, the combined company is expected to operate under the name Kalaris Therapeutics, Inc.
Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease who required frequent anti-VEGF injections before enrolling in the trial.
The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing a therapy for dry age-related macular degeneration, one of the leading causes of blindness in older adults.
A Q&A with PPP Committee Cornea/External Disease Panel member Daniel S. Choi, MD.
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.
A discussion with Shigeru Kinoshita, MD, PhD; and Edward J. Holland, MD.
The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.
A PDUFA decision date of April 2, 2025 has been assigned
SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular hypertension. Designed for implantation during cataract surgery, the platform delivers bimatoprost to lower intraocular pressure for up to 3 years.
Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.
The designations underscore the unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists.
The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.
This retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.
Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The therapy improved vision, reduced central corneal thickness, and demonstrated strong safety, offering an alternative to corneal transplants.
